13 October 2026 Punjab Khabarnama Bureau : Omeprazole is widely prescribed to manage acid-related digestive conditions, including gastroesophageal reflux disease (GERD), heartburn and stomach ulcers. However, research suggests that prolonged use of proton pump inhibitors (PPIs), the class of medicines to which omeprazole belongs, may be associated with an increased risk of small intestinal bacterial overgrowth (SIBO).
SIBO occurs when excessive numbers of bacteria accumulate in the small intestine, potentially causing bloating, abdominal discomfort, gas and changes in bowel habits. Although acid-suppressing medicines can be highly effective and necessary for many patients, understanding their potential effects on the gut microbiome is important, particularly when treatment continues for months or years. <Cite refs={[“turn257284search1″,”turn257284search6”]}/>
What Is Omeprazole and How Does It Work?
Omeprazole belongs to a group of medicines called proton pump inhibitors. These medicines reduce the amount of acid produced by the stomach by blocking the acid-secreting proton pumps in stomach cells.
Doctors commonly prescribe omeprazole for acid reflux, stomach and duodenal ulcers, and certain other conditions involving excessive acid or damage to the digestive tract. It may also be used alongside antibiotics to treat Helicobacter pylori infection.
Reducing stomach acid helps relieve symptoms and allows damaged tissue to heal. Gastric acid also serves as one of the body’s natural defences against microorganisms entering through food and drink.
When acid production is suppressed, some bacteria may survive passage through the stomach more easily. Researchers believe this change may contribute to alterations in the digestive tract’s microbial environment and potentially increase susceptibility to bacterial overgrowth in the small intestine. However, not everyone who takes omeprazole develops SIBO. <Cite refs={[“turn257284search1″,”turn257284search6”]}/>
What Is Small Intestinal Bacterial Overgrowth?
Small intestinal bacterial overgrowth, commonly known as SIBO, is a condition in which excessive bacteria are present in the small intestine, where bacterial populations are normally lower than in the large intestine.
The condition can interfere with digestion and nutrient absorption. Depending on the type and activity of the bacteria involved, it may contribute to fermentation of carbohydrates, gas production and gastrointestinal symptoms.
Common symptoms include:
- Abdominal bloating, particularly after meals.
- Excessive gas and flatulence.
- Abdominal discomfort or cramping.
- Diarrhoea or changes in bowel habits.
- In some cases, nutrient deficiencies and unintended weight loss.
These symptoms are not unique to SIBO. Irritable bowel syndrome, food intolerances, coeliac disease and other digestive conditions can cause similar problems. A proper medical assessment is therefore important before attributing persistent symptoms to bacterial overgrowth.
Why Long-Term Acid Suppression May Increase SIBO Risk
Stomach acid helps limit the survival of microorganisms entering the upper digestive tract. By reducing acidity, omeprazole may weaken part of this protective barrier.
A systematic review and meta-analysis published in the Journal of Clinical Medicine in July 2025 examined 29 studies involving 3,682 PPI users and 2,907 controls. Researchers found that PPI use was associated with higher odds of SIBO, although the results varied considerably between studies.
The analysis reported an overall odds ratio of 2.14 for SIBO among PPI users compared with controls. A subgroup analysis also found higher risk estimates among people using PPIs for more than six months. <Cite refs={[“turn257284search1″,”turn257284search2”]}/>
These findings suggest a possible relationship between prolonged acid suppression and changes in intestinal bacteria. However, the studies do not prove that omeprazole directly causes SIBO in every patient. Differences in patients’ underlying illnesses, diagnostic methods and other risk factors may influence the results.
Who May Be More Vulnerable?
Not everyone taking omeprazole faces the same risk. The likelihood of developing SIBO may be influenced by a combination of medication use and other health conditions.
People taking PPIs for extended periods: Long-term treatment may be associated with a greater likelihood of SIBO, although individual risk varies.
People with impaired intestinal movement: Conditions that slow the movement of food through the digestive tract can make bacterial accumulation more likely.
People with previous gastrointestinal surgery: Certain operations can alter intestinal anatomy or movement, potentially increasing susceptibility.
People with underlying digestive disorders: Some intestinal diseases and conditions affecting normal digestive function may contribute to bacterial overgrowth.
People experiencing persistent digestive symptoms: Ongoing bloating, abdominal discomfort or diarrhoea warrant assessment, particularly when symptoms begin or change during long-term medication use.
The presence of one or more risk factors does not establish a diagnosis. Healthcare professionals need to evaluate the full clinical picture before deciding whether SIBO testing is appropriate.
How Is SIBO Diagnosed?
Doctors may recommend hydrogen and methane breath testing when SIBO is suspected. These tests measure gases produced when bacteria metabolise a test sugar, usually glucose or lactulose.
In selected cases, a sample of fluid from the small intestine may be collected and examined for bacterial growth. This method is more invasive and is not routinely necessary for every patient.
Breath tests have limitations, and their results must be interpreted alongside symptoms, medical history and other findings. Because several digestive conditions produce similar symptoms, self-diagnosis based on bloating alone is unreliable.
If symptoms develop while taking omeprazole, patients should discuss them with their healthcare professional rather than stopping the medicine or beginning antibiotics independently.
Can SIBO Risk Be Reduced Without Stopping Omeprazole?
The first step is to review why the medicine was prescribed and whether the current dose and duration remain appropriate.
For some conditions, such as severe erosive oesophagitis or certain ulcer-related risks, long-term PPI treatment may be medically necessary. Clinical reviews recommend continuing treatment when there is a clear indication and using the lowest effective dose appropriate for the patient’s condition.
For people without a continuing indication, a clinician may consider reducing the dose, switching to an alternative treatment or attempting supervised discontinuation. Stopping a PPI can temporarily increase acid-related symptoms, so a personalised plan may be helpful.
Other measures include reviewing medicines that affect intestinal movement, managing underlying digestive disorders and following an appropriate, balanced diet. Patients should not use restrictive diets, probiotics or antibiotics as substitutes for medical evaluation.
When Should You Seek Medical Advice?
Anyone experiencing persistent diarrhoea, worsening bloating, unexplained weight loss or continuing abdominal pain should consult a healthcare professional. Urgent assessment is appropriate for severe abdominal pain, repeated vomiting, gastrointestinal bleeding or signs of significant dehydration.
People taking omeprazole for a recognised medical condition should not assume that digestive symptoms automatically indicate SIBO. A clinician can determine whether the symptoms are medication-related, caused by another condition or require further testing.
The Bottom Line
Omeprazole remains an important treatment for several acid-related disorders. Research indicates that long-term PPI use may be associated with SIBO, but the evidence does not establish a direct cause-and-effect relationship in every patient.
The most appropriate approach is to review long-term medication use periodically, investigate persistent digestive symptoms and balance potential risks against the benefits of treatment. Patients should make medication changes only in consultation with their healthcare professional.
Disclaimer: This article is for general health information and does not replace professional medical advice, diagnosis or treatment.